查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087929

瘧疾疫苗市場：2026-2032年全球市場預測（依疫苗類型、年齡層、接種方案、最終用戶和接種途徑分類）

Malaria Vaccine Market by Vaccine Type, Age Group, Dosage Schedule, End User, Route Of Administration - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，瘧疾疫苗市場規模將達到 6.2332 億美元，複合年成長率為 8.79%。

主要市場統計數據
基準年 2025 3.4543億美元
預計年份：2026年 3.7356億美元
預測年份 2032 6.2332億美元
複合年成長率 (%) 8.79%

隨著瘧疾疫苗接種從長期試驗計畫過渡到國家兒童免疫規劃，瘧疾疫苗市場顯然正進入擴張階段。這項需求也得到了數據的佐證。根據世界衛生組織（世衛組織）估計，2023年全球將確診2.63億例瘧疾病例，造成59.7萬人死亡，其中撒哈拉以南非洲五歲以下兒童的死亡負擔最為沉重。

目前，世界衛生組織建議的兩種瘧疾疫苗——RTS,S/AS01 和 R21/Matrix-M——對市場競爭格局和公共衛生狀況產生了重大影響。這些疫苗的引入擴大了疫苗生產商、國際衛生資助機構、國家瘧疾控制規劃、低溫運輸營運商和監測合作夥伴在與殺蟲劑處理蚊帳、季節性瘧疾化學預防、診斷和抗瘧治療密切相關的生態系統中的作用。

瘧疾疫苗格局的變革性變化

最顯著的變化是從「概念驗證」轉向「方案實施」。世衛組織2021年RTS,S/AS01建議和2023年R21/Matrix-M建議創造了兩種疫苗可供選擇的環境，提高了採購柔軟性，並增強了流行國家分階段部署瘧疾疫苗的信心。

人工智慧（AI）的累積影響

人工智慧正透過加速抗原發現、改進蛋白質結構建模以及支持對瘧疾原蟲複雜生命週期各個階段免疫反應的分析，開始影響瘧疾疫苗的價值鏈。這些能力至關重要，因為惡性瘧原蟲的生物學特性非常複雜，這使得疫苗研發迄今一直充滿挑戰。

關鍵區域洞察：亞太地區、非洲、歐洲和美洲

非洲仍然是瘧疾疫苗需求的主要中心，根據世界衛生組織估計，全球約94%的瘧疾病例和95%的瘧疾相關死亡病例都發生在非洲地區。在喀麥隆等國定期部署疫苗，並在全球疫苗免疫聯盟（Gavi）的廣泛支持下擴大疫苗接種範圍，使該地區成為疫苗供應、安全監測、社區接受度以及在兒童中檢驗疫苗真實有效性的主要試驗場。

主要組織集團概況：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東南亞國協，瘧疾風險因地區而異，邊境地區、森林地區和大量外來務工人員聚集地區的瘧疾風險高於高度都市化的市場地區，因此，監測、有針對性的免疫接種計劃和跨境合作至關重要。雖然海灣合作理事會（GCC）國家國內瘧疾負擔相對較輕，但它們仍然透過旅行者健康管理、人道主義援助、國家衛生投資以及支持流行地區的疾病控制計畫發揮著至關重要的作用。

對主要瘧疾疫苗市場關鍵國家的洞察

美國和加拿大主要是瘧疾疫苗研發、資金、旅遊醫學和監管的市場，而墨西哥則繼續專注於監測和集體爆發預防，以期最終根除瘧疾。巴西是拉丁美洲瘧疾疫苗最重要的國家，因為瘧疾感染集中在亞馬遜地區，而該地區在疫苗取得、人員流動和監測方面面臨的挑戰，決定了其預防策略。

為行業領導者提供的實用建議

行業領導者應優先考慮受影響國家的准入策略，包括可預測的價格、技術轉移以及與國家疫苗接種計劃相符的供應承諾。製造商必須制定生產力計畫計劃，將分階段部署、季節性、國家準備和採購週期等因素考慮在內，而不能僅依賴傳統的商業性需求。

調查方法

本執行摘要基於經過核實的二手研究和市場三角測量，利用公開可獲得的證據，包括世衛組織瘧疾報告、世衛組織疫苗建議、疫苗引進文件、多邊免疫管道的採購情況、同行評審的檢驗研究和國家瘧疾控制資訊。

結論

瘧疾疫苗市場不再只是一個理論概念。隨著世界衛生組織推薦產品的推出、各國接種率的不斷提高以及全球資金籌措機制的建立，瘧疾疫苗接種正成為降低瘧疾高發地區兒童發病率和死亡率的實際有效手段。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 瘧疾疫苗市場：依疫苗類型分類

  • 結合疫苗
  • 減毒活疫苗
  • 藥效疫苗
    • 常規mRNA
    • 自擴增mRNA
  • 次單位疫苗
  • 病毒載體疫苗
    • 腺病毒載體
    • MVA 向量

第8章：瘧疾疫苗市場：依年齡層別分類

  • 青少年/成人
  • 兒童
    • 學前班
    • 學齡
  • 嬰兒

第9章：瘧疾疫苗市場：依劑量方案分類

  • 單一劑量
  • 接種疫苗 3 次
  • 兩劑疫苗

第10章 瘧疾疫苗市場：依最終用戶分類

  • NGO
  • 私人診所
  • 公共免疫計劃
    • 區域項目
    • 國家計劃

第11章：瘧疾疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 口服
  • 皮下

第12章：瘧疾疫苗市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：瘧疾疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 瘧疾疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • BioNTech SE
  • Emergent BioSolutions Inc.
  • GSK plc
  • Instituto Butantan
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • PathWest Laboratory Medicine WA
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Private Limited
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
Product Code: MRR-035DA3C63710

The Malaria Vaccine Market is projected to grow by USD 623.32 million at a CAGR of 8.79% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 345.43 million
Estimated Year [2026] USD 373.56 million
Forecast Year [2032] USD 623.32 million
CAGR (%) 8.79%

The malaria vaccine market is entering a defined scale-up phase as immunization moves from long-running pilot programs into national childhood vaccination schedules. The need is measurable: the World Health Organization reported an estimated 263 million malaria cases and 597,000 deaths in 2023, with children under five in sub-Saharan Africa bearing the highest mortality burden.

Two WHO-recommended malaria vaccines now shape the competitive and public health landscape: RTS,S/AS01 and R21/Matrix-M. Their adoption is expanding the role of vaccine manufacturers, global health funders, national malaria control programs, cold-chain providers, and surveillance partners in an ecosystem that remains closely tied to insecticide-treated nets, seasonal malaria chemoprevention, diagnostics, and antimalarial treatment.

Transformative Shifts in the Malaria Vaccine Landscape

The most important shift is the transition from proof of concept to programmatic delivery. WHO's 2021 recommendation of RTS,S/AS01 and 2023 recommendation of R21/Matrix-M created a two-vaccine environment, improving procurement flexibility and increasing confidence among endemic countries planning phased malaria vaccine rollouts.

Market dynamics are also changing as demand is driven less by private-pay channels and more by public immunization budgets, Gavi-supported introductions, UNICEF procurement, and ministries of health. Climate variability, insecticide resistance, urban transmission, and population mobility are increasing the importance of integrated malaria prevention strategies, positioning vaccines as a complementary tool rather than a standalone intervention.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the malaria vaccine value chain by accelerating antigen discovery, improving protein-structure modeling, and supporting immune-response analysis across complex parasite life-cycle stages. These capabilities are relevant because Plasmodium falciparum has biological complexity that has historically made vaccine development difficult.

AI is also strengthening operational execution. Predictive analytics can support clinical trial-site selection, adverse-event signal detection, supply planning, and cold-chain optimization in areas where seasonal transmission creates sharp fluctuations in need. For manufacturers and public health agencies, the cumulative impact is faster decision-making, better allocation of limited doses, and more targeted post-introduction surveillance.

Key Regional Insights: Asia-Pacific, Africa, Europe, and the Americas

Africa remains the center of malaria vaccine demand because WHO attributes about 94% of global malaria cases and 95% of malaria deaths to the African region. Routine introductions in countries such as Cameroon and broader Gavi-supported expansion are making the region the primary proving ground for vaccine delivery, safety monitoring, community acceptance, and real-world effectiveness in children.

Asia-Pacific has a mixed profile: India and parts of Southeast Asia continue to manage malaria transmission, while China has achieved WHO malaria-free certification, creating a region that combines disease-control needs with vaccine manufacturing and research capabilities. North America and Europe are primarily innovation, funding, regulatory, and travel-medicine hubs that support malaria vaccine development, evaluation, and global health financing. Latin America's need is concentrated in Amazon basin transmission pockets, while the Middle East has selective risk areas and procurement relevance through humanitarian and global health financing. Africa remains the largest demand pool, but global participation is distributed across R&D, production, financing, regulation, and implementation.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries face heterogeneous malaria risk, with higher relevance in border, forest, and migrant-worker settings than in highly urbanized markets, making surveillance, targeted immunization planning, and cross-border coordination important. GCC countries are less exposed to domestic malaria burden but remain relevant through travel health, humanitarian assistance, sovereign health investments, and support for disease-control programs in endemic regions.

The European Union and G7 are central to research funding, regulatory science, manufacturing partnerships, and global procurement support for malaria vaccines. BRICS brings together both high-burden and high-capacity markets, notably India's disease-control and vaccine-production role, China's elimination experience and manufacturing capacity, and Brazil's Amazon-focused malaria challenge. NATO is not a malaria market grouping, yet member countries contribute through military medicine, deployment health, outbreak preparedness, and global health security financing that can support vaccine readiness in endemic regions.

Key Country Insights Across Major Malaria Vaccine Markets

The United States and Canada are primarily R&D, donor, travel-medicine, and regulatory markets, while Mexico continues to focus on elimination-oriented surveillance and outbreak prevention. Brazil is the most important listed Latin American country for malaria vaccine relevance because transmission is concentrated in the Amazon region, where access, mobility, and surveillance challenges shape prevention strategies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain contribute through research institutions, development finance, regulatory expertise, vaccine science, and imported malaria management, while Russia has limited endemic-market relevance but retains scientific and regional health capacity. China's WHO-certified malaria-free status strengthens its role in surveillance, elimination experience, and manufacturing; India remains central due to its malaria burden, national control efforts, and vaccine industry capacity. Japan, Australia, and South Korea contribute through biomedical R&D, financing, regional health-security programs, and partnerships supporting malaria control across Asia-Pacific.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize endemic-country access strategies, including predictable pricing, technology transfer, and supply commitments aligned with national immunization schedules. Manufacturers must design capacity plans around phased rollout, seasonality, country readiness, and procurement cycles rather than conventional commercial demand alone.

Leaders should also invest in pharmacovigilance, implementation research, and combination prevention evidence that demonstrates how malaria vaccines perform alongside insecticide-treated nets, chemoprevention, diagnostics, and case management. Strategic partnerships with global health agencies, immunization financiers, procurement bodies, African ministries of health, and local manufacturers will be essential to building trust, accelerating adoption, and reducing delivery bottlenecks.

Research Methodology

This executive summary is built from verified secondary research and market triangulation using publicly available evidence from WHO malaria reporting, WHO vaccine recommendations, vaccine introduction materials, procurement context from multilateral immunization channels, peer-reviewed vaccine studies, and national malaria control information.

The analysis evaluates epidemiology, policy adoption, product availability, funding pathways, manufacturing capacity, regulatory direction, and regional disease burden. Insights are cross-checked against multiple authoritative sources to avoid unsupported market claims, market sizing, or forecasting, and to ensure that conclusions reflect current malaria vaccine science, public health implementation, and procurement realities.

Conclusion

The malaria vaccine market is no longer theoretical. WHO-recommended products, expanding national introductions, and global financing mechanisms are turning malaria immunization into a practical tool for reducing childhood morbidity and mortality in high-burden settings.

Progress will depend on sustained evidence generation, affordable supply, country readiness, community acceptance, and integration with established malaria control measures. Organizations that combine scientific innovation with equitable access, reliable delivery, and strong surveillance will be best positioned to shape the next phase of malaria vaccine impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Malaria Vaccine Market, by Vaccine Type

  • 7.1. Conjugate Vaccine
  • 7.2. Live Attenuated Vaccine
  • 7.3. Mrna Vaccine
    • 7.3.1. Conventional Mrna
    • 7.3.2. Self Amplifying Mrna
  • 7.4. Subunit Vaccine
  • 7.5. Viral Vector Vaccine
    • 7.5.1. Adenovirus Vector
    • 7.5.2. Mva Vector

8. Malaria Vaccine Market, by Age Group

  • 8.1. Adolescent & Adult
  • 8.2. Child
    • 8.2.1. Preschool
    • 8.2.2. School Age
  • 8.3. Infant

9. Malaria Vaccine Market, by Dosage Schedule

  • 9.1. Single Dose
  • 9.2. Three Dose
  • 9.3. Two Dose

10. Malaria Vaccine Market, by End User

  • 10.1. NGOs
  • 10.2. Private Clinics
  • 10.3. Public Immunization Programs
    • 10.3.1. Local Programs
    • 10.3.2. National Programs

11. Malaria Vaccine Market, by Route Of Administration

  • 11.1. Intramuscular
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Malaria Vaccine Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Malaria Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Malaria Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AstraZeneca plc
  • 16.2. Bharat Biotech International Limited
  • 16.3. BioNTech SE
  • 16.4. Emergent BioSolutions Inc.
  • 16.5. GSK plc
  • 16.6. Instituto Butantan
  • 16.7. Johnson & Johnson
  • 16.8. Merck & Co., Inc.
  • 16.9. Moderna, Inc.
  • 16.10. Novavax, Inc.
  • 16.11. PathWest Laboratory Medicine WA
  • 16.12. Pfizer Inc.
  • 16.13. Sanofi S.A.
  • 16.14. Serum Institute of India Private Limited
  • 16.15. Takeda Pharmaceutical Company Limited
  • 16.16. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALARIA VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MALARIA VACCINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MALARIA VACCINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MALARIA VACCINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRNA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MRNA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADENOVIRUS VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADENOVIRUS VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADENOVIRUS VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MVA VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MVA VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MVA VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADOLESCENT & ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADOLESCENT & ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADOLESCENT & ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRESCHOOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRESCHOOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRESCHOOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SCHOOL AGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SCHOOL AGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SCHOOL AGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THREE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THREE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THREE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TWO DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TWO DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TWO DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NGOS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NGOS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NGOS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PRIVATE CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRIVATE CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRIVATE CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PUBLIC IMMUNIZATION PROGRAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PUBLIC IMMUNIZATION PROGRAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PUBLIC IMMUNIZATION PROGRAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LOCAL PROGRAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LOCAL PROGRAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LOCAL PROGRAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NATIONAL PROGRAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NATIONAL PROGRAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NATIONAL PROGRAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. GCC MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GCC MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 160. GCC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. G7 MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. G7 MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 190. G7 MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. NATO MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 200. NATO MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. NATO MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 344. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 352. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 354. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)